: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE MINERVA NEUROSCIENCES ANNOUNCES UPDATE ON MIN-101 CLINICAL DEVELOPMENT PROGRAM Enrol

MINERVA NEUROSCIENCES ANNOUNCES UPDATE ON MIN-101 CLINICAL

Enrollment completed in European Phase IIb trial and

Investigational New Drug (IND) application accepted by U.S. FDA

Waltham, MA, December 29, 2015 Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development

of therapies to treat central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company s Investigational New Drug (IND) application for MIN-101, a first-in-class 5-HT2a and sigma2

antagonist in clinical development for the treatment of schizophrenia.

In addition, the Company announced the completion of the enrollment of a total of

244 patients in a randomized, placebo-controlled double-blind European Phase IIb clinical trial of MIN-101. The primary objective of this trial is to evaluate the efficacy of MIN-101 compared to placebo in improving the negative symptoms of

schizophrenic patients. Additional objectives include the assessment of cognitive symptoms and overall symptomatology of the disease following treatment with MIN-101. Topline results from the core 12-week treatment evaluation period are expected in

the second quarter of 2016.

Acceptance of the IND for MIN-101 is an important step toward the initiation of advanced-stage clinical testing of this

compound in the U.S. following the results of our ongoing Phase IIb trial in Europe, said Remy Luthringer, president and chief executive officer of Minerva. We will be continuing our dialogue with the FDA as part of our overall planning

for late-stage clinical testing in the U.S.

About Minerva Neurosciences

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products to treat

CNS diseases. Minerva s proprietary compounds include: MIN-101, in Phase IIb development for schizophrenia; MIN-202 (JNJ-42847922), in Phase IIa and Phase Ib development for insomnia and the adjunctive treatment of major depressive disorder

(MDD), respectively; MIN-117, in development for MDD; and MIN-301, in pre-clinical development for Parkinson s disease. Minerva s common stock is listed on the NASDAQ Global Market under the symbol NERV. For more information,

please visit www.minervaneurosciences.com.

Forward-Looking Safe Harbor Statement

This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of

1995, as amended. Forward-looking statements are statements that are not historical facts, reflect management s expectations as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include

herein with respect to the timing and results of future clinical milestones with MIN-101; the clinical and therapeutic potential of MIN-101; our ability to successfully develop and commercialize

MIN-101; the sufficiency of our current cash position to fund our operations; and management s ability to successfully achieve its goals. These forward-looking statements are based on our current expectations and may differ materially from

actual results due to a variety of factors including, without limitation, whether MIN-101 will advance further in the clinical trials process and whether and when, if at all, it will receive final approval from the U.S. Food and Drug Administration

or equivalent foreign regulatory agencies and for which indications; whether MIN-101 will be successfully marketed if approved; whether our therapeutic product discovery and development efforts with MIN-101 will be successful; our ability to achieve

the results contemplated by our co-development agreements; management s ability to successfully achieve its goals; our ability to raise additional capital to fund our operations on terms acceptable to us; and general economic conditions. These

and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption Risk Factors in our filings with the Securities and Exchange Commission, including

our Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, filed with the Securities and Exchange Commission on November 5, 2015. Copies of reports filed with

the SEC are posted on our website at www.minervaneurosciences.com. The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update

any forward-looking statements, except as required by law.